Abstract
To compare the efficacy and complications of chemotherapy and late course three-dimensional conformal radiotherapy (3DCRT) in treating patients with stage III non-small cell lung cancer (NSCLC). All patients were divided into two groups: to receive chemotherapy and late course 3DCRT (3DCRT group), or chemotherapy and conventional fraction radiation (control group). In the 3DCRT-group, patients were given 6~15 MV X-rays with a total dose of 40 Gy, followed by 3DCRT, 2.5 Gy~3.0 Gy per fraction, 1 fraction/ every day, total 68 Gy~70 Gy; in the control group, with conventional fraction radiation the total dose was 64~66 Gy. The chemotherapy regimen in both cases was EP (VP-16 and DDP). Sixty four patients with stage III NSCLC were divided into two groups: 32 patients into 3DCRT, 32 into the control group. One and 2-year survival rates in 3DCRT and control group were 87.5%, 56.3%mad 65.6%, 34.4%, respectively (P<0.05); local control rates were 90.6%, 81.3% and 65.6%, 53.1%, respectively (P<0.05). Chemotherapy and late course 3DCRT is associated with improved survival rate in patients with stage III NSCLC with good tolerability.
Highlights
75% of lung cancer, a leading cause of cancer-related death worldwide, is non-small cell lung cancer (NSCLC) (Ferlay et al, 2001)
Patients and Methods: All patients were divided into two groups: to receive chemotherapy and late course 3DCRT (3DCRT group), or chemotherapy and conventional fraction radiation
Treatment All patients were divided into two groups: to receive chemotherapy and late course 3DCRT (3DCRT group), or to receive chemotherapy and conventional fraction radiation(control group)
Summary
75% of lung cancer, a leading cause of cancer-related death worldwide, is non-small cell lung cancer (NSCLC) (Ferlay et al, 2001). Most patients in China present with locally advanced stage III or IV disease. Current practice for treatment includes several newer generation agents, e.g. vinorelbine, gemcitabine, paclitaxel or docetaxel with a platinum agent, no combination is a gold standard (Non-Small Cell Lung Cancer Collaborative Group, 1995; Schiller et al, 2002). For inoperable NSCLC, radiotherapy is a treatment option, but 5 -year survival rate is less than 10%; localregional failure and distant metastasis are main reasons for treatment failure. In order to improve treatment efficacy of stage III NSCLC, we designed a comparative study: one group received chemotherapy plus concurrent late course conformal radiotherapy, another group received chemotherapy plus concurrent conventional radiotherapy
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
